New study targets diabetes disparities in black patients

This study looks at how two types of FDA-approved diabetes medicines—GLP-1 receptor agonists and SGLT-2 inhibitors—affect the pancreas's ability to make insulin in Black patients with type 2 diabetes. About 60 adults will take one of the drugs for 16 weeks, and researchers will measure changes in beta cell function using a glucose test. The goal is to understand which drug works better for this group, since Black patients often have worse diabetes outcomes.